Reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
=== Europe === The presence of Medical Physicists at Expert level ('Medical Physics Experts') in healthcare in the European Union is required by the 2013/59/Euratom directive. The European Federation of Organisations for Medical Physics(EFOMP) has defined a detailed inventory of learning outcomes for Medical Physics Experts in terms of Knowledge, Skills and Competences (the latter in Europe means 'responsibilities'). In Europe the professional preparation for Medical Physicists typically consists of a first degree in Physics or equivalent (e.g., biophysics, electrical or mechanical engineering, computing), a Masters in Medical Physics and a 2-year training Residency. The European Commission has produced 'European Guidelines on the Medical Physics Expert'.
The concept of DNA-encoding was first described in a theoretical paper by Sydney Brenner and Richard Lerner in 1992 in which was proposed to link each molecule of a chemically synthesized entity to a particular oligonucleotide sequence constructed in parallel and to use this encoding genetic tag to identify and enrich active compounds. In 1993 the first practical implementation of this approach was presented by J Nielsen, S. Brenner and K. Janda and similarly by the group of M.A. Gallop. Brenner and Janda suggested to generate individual encoded library members by an alternating parallel combinatorial synthesis of the heteropolymeric chemical compound and the appropriate oligonucleotide sequence on the same bead in a “split-&-pool”-based fashion (see below). Since unprotected DNA is restricted to a narrow window of conventional reaction conditions, until the end of the 1990s a number of alternative encoding strategies were envisaged (i.e. MS-based compound tagging, peptide encoding, haloaromatic tagging, encoding by secondary amines, semiconductor devices.), mainly to avoid inconvenient solid phase DNA synthesis and to create easily screenable combinatorial libraries in high-throughput fashion. However, the selective amplificability of DNA greatly facilitates library screening and it becomes indispensable for the encoding of organic compounds libraries of this unprecedented size. Consequently, at the beginning of the 2000s DNA-combinatorial chemistry experienced a revival.
The bloom strength of a gelatine mixture is the measure of how strong it is. It is defined by the force in grams required to press a 12.5 mm (0.49 in) diameter plunger 4 mm (0.16 in) into 112 g (4.0 oz) of a standard 6.67% w/v gelatine gel at 10 °C (50 °F). The bloom strength of a gel is useful to know when determining the possibility of substituting a gelatine of one bloom strength for a gelatine of another. One can use the following equation:
Sources: en.wikipedia.org
He also coined technical terms such as “isodynamics,” “isoclines,” and “magnetic storm,” and was the first to describe the magnetic equator. Humboldt’s mapping and cartographic achievements set new standards for accuracy and integration. In Recueil d’observations astronomiques, d’opérations trigonométriques et de mesures barométriques, he presented maps that combined astronomical observations for latitude and longitude, triangulation, and barometric measurements of elevation. His maps of the Orinoco River, the Andes, the Valley of Mexico, and other regions provided unprecedented detail and clarity. In Mexico, he oversaw the production of a comprehensive map that synthesized political, economic, ethnographic, and physical information, setting a new standard for thematic maps. Humboldt’s Essai politique sur le royaume de la Nouvelle-Espagne (Political Essay on the Kingdom of New Spain) and Essai politique sur l’île de Cuba (Political Essay on the Island of Cuba) exemplify his approach to regional geography. These works combined exhaustive statistical data with economic, social, and physical analysis, offering the first modern regional studies of Mexico and Cuba. In Mexico, Humboldt’s assessments of mining resources, particularly silver, drew international attention and had significant economic repercussions. His Cuban essay was notable for its forceful condemnation of slavery. In both cases, Humboldt’s integration of field observations, statistical analysis, and critical commentary created a template for future regional and economic geography.
dermo-subcutaneous muscular system of integument This functional component of avian skin consists of the smooth muscle of the apteria and striated subcutaneous muscles. The smooth muscles of the apteria counteract the horizontal forces experienced by the feather follicles. The striated subcutaneous muscles also adjust the position of the feather follicles in the directions the smooth muscle cannot. Together this system acts as an integrated muscular system that properly positions the feather tracts on the body of the bird.
Although antivenom saves many lives, mortality due to black mamba envenomation is still at 14%, even with antivenom treatment. In addition to antivenom treatment, endotracheal intubation and mechanical ventilation are required for supportive therapy.
=== Video games === Major Force appears as a boss in DC Universe Online, voiced by Alexander Brandon. This version works for Amanda Waller. Major Force appears as a character summon in Scribblenauts Unmasked: A DC Comics Adventure.
Sources: en.wikipedia.org
=== Transcriptional regulation === Histones can be ubiquitinated, usually in the form of monoubiquitylation, although polyubiquitylated forms do occur. Histone ubiquitylation alters chromatin structure and allows the access of enzymes involved in transcription. Ubiquitin on histones also acts as a binding site for proteins that either activate or inhibit transcription and also can induce further post-translational modifications of the protein. These effects can all modulate the transcription of genes.
== Etymology == The Oxford English Dictionary had cited the first known usage in the English language to a Scottish newspaper, The People's Journal, in 1848: "A war among the great powers is now necessarily a world-war." The term "world war" is used by Karl Marx and his associate, Friedrich Engels, in a series of articles published around 1850 called The Class Struggles in France. Rasmus B. Anderson in 1889 described an episode in Teutonic mythology as a "world war" (Swedish: världskrig), justifying this description by a line in an Old Norse epic poem, "Völuspá: folcvig fyrst I heimi" ("The first great war in the world"). German writer August Wilhelm Otto Niemann used the term "world war" in the title of his anti-British novel, Der Weltkrieg: Deutsche Träume (The World War: German Dreams) in 1904, published in English as The Coming Conquest of England. The term "first world war" was first used in September 1914 by German biologist and philosopher Ernst Haeckel, who claimed that "there is no doubt that the course and character of the feared 'European War' ... will become the first world war in the full sense of the word", citing a wire service report in the Indianapolis Star on 20 September 1914. In English, the term "First World War" was used by Lieutenant Colonel Charles à Court Repington as the title of his memoirs, published in 1920; he had previously noted his discussion on the matter with a Major Johnstone of Harvard University in his diary entry of September 10, 1918. The term "World War I" was coined by Time magazine on page 28 of its June 12, 1939, issue.
== Mobile network speeds == In a 2017 report published by the UK firm, OpenSignal, Thailand ranked 70 of 89 nations (1=fastest, 89=slowest). The report drew on 19 billion samples collected by more than one million OpenSignal users from November 2016 to January 2017. Thai mobile users can expect an average mobile data speed of 6.09 Mbps compared with number one South Korea's 37.5 Mbps. Other ASEAN nations ranked were Singapore, ranked fourth; Brunei, 46; Malaysia 57 (7.86 Mbps); Cambodia, 74; Myanmar, 78 (4.81 Mbps); Indonesia, 80 (4.72 Mbps); Philippines, 86 (3.33 Mbps).
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.